The UK’s surprise decision to leave the EU has caused a great deal of uncertainty about the country’s future, not least among those working in the UK biopharmaceutical and broader life sciences industry.
The annual U.S. economic burden of respiratory disease is more than $106 billion. Appropriate therapy can reduce direct healthcare costs as well as indirect costs such as lost worker productivity. The combined U.S. market for respiratory products totalled more than $4.4 billion in 2015.
The large and burgeoning global market for implantable neurostimulation devices is approaching nearly $4 billion worldwide. Despite lingering economic uncertainty and financial constraints that have affected many other medical device markets, this market is undergoing significant technological advancement due to heavy R&D and investment efforts by dozens of innovative startups and leading medical device companies.
More than 40% of people in the U.S. say they have experienced recent pain, with 8% suffering from chronic pain. Direct healthcare costs associated with the treatment of pain total nearly $300 billion annually.
Cardiovascular diseases (CVDs) are the leading causes of death throughout the world. Based on Datamonitor Healthcare estimates, approximately 500 million CVD-related cases occurred in the United States (U.S.), China, Japan, and the five major countries of Europe (France, Germany, Italy, Spain, and the United Kingdom [U.K.]).
In the United States (U.S.), approximately 85.6 million adults have at least one type of cardiovascular disease (CVD), a broad group of disorders that affect the heart and circulatory system. Cardiovascular disease in all its forms accounts for more deaths than any other major cause in the U.S.
The Asia-Pacific (APAC) region is a part of the world which includes several developing and developed countries. Countries covered in this report include Australia, China, India, Japan, Malaysia, South Korea, Thailand, and Vietnam.
This report covers the large, highly competitive, technology driven Global Market for Radiation Therapy Systems—valued at nearly $4.3 billion in 2015.
Spine disorders are a leading driver of healthcare costs worldwide, and range in severity from mild pain and loss of feeling to extreme pain and paralysis. These disorders are primarily caused by degenerative conditions in the spine, deformity, tumors and trauma.
This report provides a summary of the nearly $2 billion U.S. patient monitoring devices market.
Pharmacotherapy represents the first-line treatment in the management of most chronic and transient medical conditions warranting therapeutic intervention in the U.S.
U.S. Markets for Advanced Wound Care Products
This report examines the healthcare trends in Asia-Pacific countries (Japan, China, South Korea, India, Thailand, Vietnam, Malaysia and Australia), as well as analyzes and forecasts (toward 2019).
The United States (U.S.) market for stroke management products, which encompasses diagnostic and therapeutic systems, is a market composed of old and new technologies that are often used together in order to prevent and treat stroke. Improvements in stroke diagnostic systems will facilitate the delivery of timely stroke therapies within the optimum treatment window for patients suffering from stroke.
The molecular diagnostic products market is the highest growth segment of the global in vitro diagnostics (IVDs) market valued at an estimated $5.3 billion in 2014 and projected to grow at a compound annual growth rate of 6.6% to $7.3 billion by the year 2019.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!